Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Hess

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Journal of Comparative Effectiveness Research|March 14, 2018
Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groupsKristin M Sheffield, Lee Bowman, David M Smith, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 12, 2002
Intake of supplemental and total fiber and risk of colorectal adenoma recurrence in the wheat bran fiber trialElizabeth T Jacobs, Anna R Giuliano, Denise J Roe, et al.
Clinical Lung Cancer|April 20, 2023
Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice SettingAnthony N Sireci, Peter M Krein, Lisa M Hess, et al.
Journal of Patient-Reported Outcomes|December 18, 2024
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancerAntoine Regnault, Laurine Bunod, Angely Loubert, et al.
Haematologica|November 30, 2023
Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparisonOthman Al-Sawaf, Min-Hua Jen, Lisa M Hess, et al.
Journal of Medical Economics|July 28, 2015
Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic reviewGebra Cuyun Carter, Denise T King, Lisa M Hess, et al.
Hospital Pharmacy|June 30, 2016
Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology PharmacyLisa M Hess, Frank N Cinfio, Stewart Wetmore, et al.
The Journal of Supportive Oncology|January 27, 2011
Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancerLisa M Hess, Setsuko K Chambers, Kenneth Hatch, et al.
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Leukemia & Lymphoma|March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database studyToby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Journal of Comparative Effectiveness Research|March 14, 2018
Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groupsKristin M Sheffield, Lee Bowman, David M Smith, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 12, 2002
Intake of supplemental and total fiber and risk of colorectal adenoma recurrence in the wheat bran fiber trialElizabeth T Jacobs, Anna R Giuliano, Denise J Roe, et al.
Clinical Lung Cancer|April 20, 2023
Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice SettingAnthony N Sireci, Peter M Krein, Lisa M Hess, et al.
Journal of Patient-Reported Outcomes|December 18, 2024
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancerAntoine Regnault, Laurine Bunod, Angely Loubert, et al.
Haematologica|November 30, 2023
Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparisonOthman Al-Sawaf, Min-Hua Jen, Lisa M Hess, et al.
Journal of Medical Economics|July 28, 2015
Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic reviewGebra Cuyun Carter, Denise T King, Lisa M Hess, et al.
Hospital Pharmacy|June 30, 2016
Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology PharmacyLisa M Hess, Frank N Cinfio, Stewart Wetmore, et al.
The Journal of Supportive Oncology|January 27, 2011
Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancerLisa M Hess, Setsuko K Chambers, Kenneth Hatch, et al.
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Leukemia & Lymphoma|March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database studyToby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
Pageof 11